Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.57 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | SRC | P12931 | 3/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | WEE1 | P30291 | 5/20 | 0.50 |
| ▸ | SIK2 | Q9H0K1 | 4/20 | 0.47 |
| ▸ | SIK1 | P57059 | 3/20 | 0.47 |
| ▸ | SIK3 | Q9Y2K2 | 3/20 | 0.47 |
| ▸ | STK4 | Q13043 | 1/20 | 0.47 |
| ▸ | STK3 | Q13188 | 1/20 | 0.47 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.47 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2261009 | 1.00 | FGFR1 (0.57) | FGFR1EGFRSRCMAPK14WEE1 | |
| SCHEMBL31532090 | 0.84 | FGFR1 (0.60) | FGFR1EGFRWEE1ABL1CDK4 | |
| SCHEMBL31532052 | 0.84 | FGFR1 (0.60) | FGFR1EGFRSRCMAPK14WEE1 | |
| SCHEMBL13553971 | 0.83 | FGFR1 (0.59) | FGFR1EGFRSRCMAPK14WEE1 | |
| SCHEMBL11914233 | 0.82 | FGFR1 (0.57) | FGFR1EGFRSRCMAPK14WEE1 | |
| SCHEMBL12120890 | 0.81 | WEE1 (0.75) | FGFR1EGFRSRCWEE1CDK4 | |
| SCHEMBL27263923 | 0.80 | WEE1 (0.41) | FGFR1EGFRSRCMAPK14WEE1 | |
| SCHEMBL29861345 | 0.80 | WEE1 (0.41) | FGFR1EGFRSRCMAPK14WEE1 | |
| SCHEMBL12365613 | 0.79 | FGFR1 (0.55) | FGFR1EGFRSRCMAPK14WEE1 | |
| SCHEMBL31532051 | 0.79 | FGFR1 (0.55) | FGFR1EGFRSRCMAPK14WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043349-A1 | PYRIMIDOPYRIDONE AND PTERIDONE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2025-03-06 | — | — | WO | disclosed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | FGFR1 1581/4885EGFR 862/4885SRC 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.